litlas
Log inCreate account

Ann D. Thor

Active 1984–2022

80
Papers
18,354
Citations
75
h-index
80
i10-index

Citations

Citations per year for Ann D. Thor1984: 1 citations1985: 9 citations1986: 28 citations1987: 46 citations1988: 40 citations1989: 21 citations1990: 32 citations1991: 28 citations1992: 42 citations1993: 51 citations1994: 86 citations1995: 103 citations1996: 73 citations1997: 119 citations1998: 123 citations1999: 109 citations2000: 189 citations2001: 183 citations2002: 160 citations2003: 187 citations2004: 168 citations2005: 188 citations2006: 166 citations2007: 126 citations2008: 151 citations2009: 176 citations2010: 170 citations2011: 163 citations2012: 163 citations2013: 128 citations2014: 119 citations2015: 106 citations2016: 90 citations2017: 85 citations2018: 78 citations2019: 232 citations2020: 256 citations2021: 194 citations2022: 132 citations2023: 95 citations2024: 127 citations2025: 62 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,086 citing papers, 35.9% of this breakdownUnited Kingdom: 399 citing papers, 6.9% of this breakdownChina: 357 citing papers, 6.1% of this breakdownItaly: 287 citing papers, 4.9% of this breakdownGermany: 248 citing papers, 4.3% of this breakdownCanada: 242 citing papers, 4.2% of this breakdownFrance: 194 citing papers, 3.3% of this breakdownJapan: 168 citing papers, 2.9% of this breakdownAustralia: 144 citing papers, 2.5% of this breakdownSpain: 125 citing papers, 2.1% of this breakdownSwitzerland: 109 citing papers, 1.9% of this breakdownNetherlands: 109 citing papers, 1.9% of this breakdown
0%35.9%Other 23.1%

Institutions

Fields

  • Medicine49.2%
  • Biochemistry, Genetics and Molecular Biology45.5%
  • Immunology and Microbiology1.8%
  • Computer Science0.7%
  • Materials Science0.6%
  • Engineering0.5%
  • Other1.7%

Topics

  • HER2/EGFR in Cancer Research6.4%
  • Breast Cancer Treatment Studies5.9%
  • Cancer-related Molecular Pathways3.7%
  • Monoclonal and Polyclonal Antibodies Research3.2%
  • Metabolism, Diabetes, and Cancer2.7%
  • Cancer Cells and Metastasis2.3%
  • Other75.8%

Coauthors

All papers

Open in search
  1. Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin

    Authors: Xiaoping Huang, Li‐Zhi Gao, Shuiliang Wang, James L. McManaman, Ann D. Thor, Xiao-He Yang, Francisco J. Esteva, Bolin Liu - Cancer Research 2010 cited by 246

  2. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide

    Authors: Dawn R. Cochrane, Sebastián Bernales, Britta M. Jacobsen, Diana M. Cittelly, Erin N. Howe, Nicholas C. D’Amato, Nicole S. Spoelstra, Susan M. Edgerton, Annie Jean, Javier Guerrero, Francisco Javier Gómez, Satyanarayana Medicherla, Iván E. Alfaro, Emma McCullagh, Paul Jedlicka, Kathleen C. Torkko, Ann D. Thor, Anthony Elias, Andrew A. Protter, Jennifer K. Richer - Breast Cancer Research 2014 cited by 432

  3. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization.

    Authors: Olli Kallioniemi, Anne Kallioniemi, Wayne Kurisu, Ann D. Thor, L C Chen, Helene S. Smith, Fred Waldman, Daniel Pinkel, Joe W. Gray - National Academy of Sciences, Proceedings of the National Academy of Sciences 1992 cited by 560

  4. Trastuzumab in the Treatment of Advanced Non-Small-Cell Lung Cancer: Is There a Role? Focus on Eastern Cooperative Oncology Group Study 2598

    Authors: Corey J. Langer, Patricia Stephenson, Ann D. Thor, Márk Vangel, David H. Johnson - Journal of Clinical Oncology 2004 cited by 225

  5. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro

    Authors: Irina Alimova, Bolin Liu, Zeying Fan, Susan M. Edgerton, Thomas E. Dillon, Stuart E. Lind, Ann D. Thor - Cell Cycle 2009 cited by 525

  6. Downregulation of erbB3 abrogates erbB2‐mediated tamoxifen resistance in breast cancer cells

    Authors: Bolin Liu, Dalia Ordonez‐Ercan, Zeying Fan, Susan M. Edgerton, Xiaohe Yang, Ann D. Thor - International Journal of Cancer 2007 cited by 157

  7. Postpartum breast involution reveals regression of secretory lobules mediated by tissue-remodeling

    Authors: Sonali Jindal, Dexiang Gao, Pat Bell, Grethe Albrektsen, Susan M. Edgerton, Christine B. Ambrosone, Ann D. Thor, Virginia F. Borges, Pepper Schedin - Breast Cancer Research 2014 cited by 102

  8. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers

    Authors: Xin‐Sheng Deng, Shuiliang Wang, Anlong Deng, Bolin Liu, Susan M. Edgerton, Stuart E. Lind, Reema S. Wahdan-Alaswad, Ann D. Thor - Cell Cycle 2012 cited by 210

  9. Metformin induces unique biological and molecular responses in triple negative breast cancer cells

    Authors: Bolin Liu, Zeying Fan, Susan M. Edgerton, Xin‐Sheng Deng, Irina Alimova, Stuart E. Lind, Ann D. Thor - Cell Cycle 2009 cited by 395

  10. Metformin-Induced Killing of Triple-Negative Breast Cancer Cells Is Mediated by Reduction in Fatty Acid Synthase via miRNA-193b

    Authors: Reema S. Wahdan-Alaswad, Dawn R. Cochrane, Nicole S. Spoelstra, Erin N. Howe, Susan M. Edgerton, Steven M. Anderson, Ann D. Thor, Jennifer K. Richer - Hormones and Cancer 2014 cited by 106

  11. Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem

    Authors: Reema S. Wahdan-Alaswad, Bolin Liu, Ann D. Thor - Cancer Drug Resistance 2020 cited by 36

  12. Glucose promotes breast cancer aggression and reduces metformin efficacy

    Authors: Reema S. Wahdan-Alaswad, Zeying Fan, Susan M. Edgerton, Bolin Liu, Xin‐Sheng Deng, Sigrid S. Árnadóttir, Jennifer K. Richer, Steven M. Anderson, Ann D. Thor - Cell Cycle 2013 cited by 126

  13. Revision of the American Joint Committee on Cancer Staging System for Breast Cancer

    Authors: S. Eva Singletary, Craig Allred, Pandora Ashley, Lawrence W. Bassett, Donald A. Berry, Kirby I. Bland, Patrick I. Borgen, Gary M. Clark, Stephen B. Edge, Daniel F. Hayes, Lorie L. Hughes, R. V. P. Hutter, Monica Morrow, David L. Page, Abram Recht, Richard L. Theriault, Ann D. Thor, Donald L. Weaver, H. Samuel Wieand, Frederick L. Greene - Journal of Clinical Oncology 2002 cited by 1,183

  14. Maspin, a Serpin with Tumor-Suppressing Activity in Human Mammary Epithelial Cells

    Authors: Zhiqiang Zou, Anthony Anisowicz, Mary J.C. Hendrix, Ann D. Thor, Mark J. Neveu, Shijie Sheng, Kristina Rafidi, Elisabeth A. Seftor, Ruth Sager - Science 1994 cited by 921

  15. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual

    Authors: S. Eva Singletary, Craig Allred, Pandora Ashley, Lawrence W. Bassett, Donald A. Berry, Kirby I. Bland, Patrick I. Borgen, Gary M. Clark, Stephen B. Edge, Daniel F. Hayes, Lorie L. Hughes, R. V. P. Hutter, Monica Morrow, David L. Page, Abram Recht, Richard L. Theriault, Ann D. Thor, Donald L. Weaver, H. Samuel Wieand, Frederick L. Greene - Surgical Clinics of North America 2003 cited by 294

  16. Downregulation of miR-342 is associated with tamoxifen resistant breast tumors

    Authors: Diana M. Cittelly, Partha Das, Nicole S. Spoelstra, Susan M. Edgerton, Jennifer K. Richer, Ann D. Thor, Frank E. Jones - Molecular Cancer 2010 cited by 188

  17. The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression.

    Authors: Chao Wang, Ann D. Thor, Dan H. Moore, Yong Zhao, Russell Kerschmann, Robert Stern, Peter H. Watson, Eva A. Turley - 1998 cited by 180

  18. Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions

    Authors: Bolin Liu, Zeying Fan, Susan M. Edgerton, Xiaohe Yang, Stuart E. Lind, Ann D. Thor - Cell Cycle 2011 cited by 145

  19. Metformin Selectively Targets Tumor-Initiating Cells in ErbB2-Overexpressing Breast Cancer Models

    Authors: Pei Zhu, Meghan B. Davis, Amanda J. Blackwelder, Nora Bachman, Bolin Liu, Susan M. Edgerton, Leonard Williams, Ann D. Thor, Xiaohe Yang - Cancer Prevention Research 2013 cited by 85

  20. Upregulation of endogenous TRAIL-elicited apoptosis is essential for metformin-mediated antitumor activity against TNBC and NSCLC

    Authors: Shuang Liu, Erik Polsdofer, Lukun Zhou, Sanbao Ruan, Hui Lyu, Defu Hou, Hao Liu, Ann D. Thor, Zhimin He, Bolin Liu - Molecular Therapy — Oncolytics 2021 cited by 21

  21. Preventing ovariectomy-induced weight gain decreases tumor burden in rodent models of obesity and postmenopausal breast cancer

    Authors: Elizabeth A. Wellberg, Karen A. Corleto, L. Allyson Checkley, Sonali Jindal, Ginger C. Johnson, Janine Higgins, Sarina Obeid, Steven M. Anderson, Ann D. Thor, Pepper J. Schedin, Paul S. MacLean, Erin D. Giles - Breast Cancer Research 2022 cited by 19

  22. Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene.

    Authors: Lawrence Zukerberg, Woo Ick Yang, Michele A. Gadd, Ann D. Thor, F C Koerner, Emmett V. Schmidt, Andrew Arnold - 1995 cited by 130

  23. Loss of Heterozygosity in Normal Tissue Adjacent to Breast Carcinomas

    Authors: Guoren Deng, You Lü, G Zlotnikov, Ann D. Thor, Helene S. Smith - Science 1996 cited by 588

  24. Relationship of Epidermal Growth Factor Receptor Expression to ErbB-2 Signaling Activity and Prognosis in Breast Cancer Patients

    Authors: Michael P. DiGiovanna, David F. Stern, Susan M. Edgerton, Steve G. Whalen, Dan H. Moore, Ann D. Thor - Journal of Clinical Oncology 2005 cited by 233